88 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
15 Feb 24
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:03am
Society of Hematology (ASH) Annual Meeting and
Exposition. The study achieved its primary endpoint of hemoglobin response and an improvement
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
treatment of polycythemia vera (PV)
Data Presentations: Presented broad set of clinical and translational data at the 65th American Society
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
; IT: Italian Society of Thal & Hemoglobinopathies Patient Registry, Jan 2021, Angelucci, et.al, 2017; FR: French registry for thal (Thuret, et.al.); ES
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
2 Nov 23
Agios Reports Business Highlights and Third Quarter 2023 Financial Results
7:02am
of clinical and translational data at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition; abstracts will be available at 9 a.m. ET today
8-K
EX-99.1
rlfq1t2rr x1
3 Aug 23
Agios Reports Business Highlights and Second Quarter 2023 Financial Results
6:38am
8-K
EX-99.1
o939985
3 Nov 22
Agios Reports Business Highlights and Third Quarter 2022 Financial Results
7:02am
8-K
EX-99.1
jj1qz5nsgg0 h1
24 Feb 22
Agios Reports Fourth Quarter and Full Year 2021 Financial Results
7:40am
8-K
EX-99.1
j6juemvl
3 Nov 21
Agios Reports Business Highlights and Third Quarter 2021 Financial Results
7:27am
8-K
EX-99.1
717ttyq60 w1f3d
29 Jul 21
Agios Reports Business Highlights and Second Quarter 2021 Financial Results
7:17am
8-K
EX-99.1
jps753 hpychy4
11 Jun 21
Other Events
7:24am
8-K
EX-99.2
j31d6satng2i 6ly
11 Jun 21
Other Events
7:24am
8-K
EX-99.1
6fjovzs
25 Feb 21
Agios Reports Fourth Quarter and Full Year 2020 Financial Results
7:17am
8-K
EX-99.1
xcngxt91ryix
26 Jan 21
Other Events
4:14pm
DEFA14A
ca4a t73xxiuo2ay
11 Jan 21
Additional proxy soliciting materials
7:17am
8-K
EX-99.1
u7zje wafp
11 Jan 21
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
7:14am
8-K
EX-99.1
mrb2fv
7 Dec 20
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
4:53pm